General
Preferred name
DOCETAXEL
Synonyms
DOCETAXEL HYDRATE ()
RP-56976 ()
Taxotere ()
NSC 628503 ()
Docetaxel (Taxotere) ()
DOCETAXEL ANHYDROUS ()
Docetaxel (Trihydrate) ()
RP-56976 (Trihydrate) ()
Docetaxel Trihydrate ()
DocetaxelTaxotereTXTRP 56976 ()
Docetaxel (hydrate) ()
Docetaxel mylan ()
Docetaxel, anhydrous ()
NSC-628503 ()
Docetaxel kabi ()
Cabazitaxel metabolite (rp56976) ()
CKD-810 ()
Docetaxel winthrop ()
RP56976 ()
Docetaxel teva pharma ()
Docefrez ()
Bind 014 ()
Docetaxel hydrate ()
XRP6976 ()
Docetaxel trihydrate ()
Taxespira (previously docetaxel hospira uk limited ) ()
Docetaxel teva ()
Docetaxel (as trihydrate) ()
Taxceus ()
Docetaxel accord ()
Docivyx ()
Beizray ()
RP 56976 ()
Docetaxel zentiva (previously docetaxel winthrop) ()
Docetaxel ()
P&D ID
PD004088
CAS
114977-28-5
148408-66-6
114915-20-7
700367-34-6
Tags
available
probe
drug
nuisance
Approved by
EMA
FDA
First approval
1995
Drug indication
breast carcinoma
Head and neck squamous cell carcinoma
Solid tumour/cancer
Drug Status
approved
withdrawn
investigational
Max Phase
4.0
Probe info
Probe type
calculated probe
Probe sources
Probe Miner (suitable probes)
Probe targets
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Docetaxel is a pan tubulin inhibitor which is a semi-synthetic analogue of paclitaxel (taxol), an extract from the bark of the rare Pacific yew tree Taxus brevifolia. (GtoPdb)
PRICE 29
DESCRIPTION Docetaxel (RP-56976) is a microtubule?depolymerization inhibitor, with an IC50 of 0.2 ¦ÌM. Docetaxel attenuates the effects of?bcl-2 and bcl-xL gene expression. Docetaxel arrests the cell cycle at G2/M and leads to cell apoptosis. Docetaxel has anti-cancer activity[1][3].
DESCRIPTION Docetaxel (RP-56976), a semi-synthetic analog of paclitaxel, is a microtubule depolymerization inhibitor (IC50=0.2 ??M) that attenuates the effects of bcl-2 and bcl-xL gene expression and exhibits apoptosis-inducing, anti-tumor activity.
DESCRIPTION Docetaxel Trihydrate (RP-56976 Trihydrate) is an antineoplastic agent and inhibits microtubule?depolymerization with an IC50 value of 0.2 ¦ÌM[1]. Docetaxel Trihydrate is a semisynthetic analog of taxol and attenuates the effects of?bcl-2?and?bcl-xL?gene expression. Docetaxel Trihydrate arrests the cell cycle at G2/M and leads to cell apoptosis[1][3].
DESCRIPTION Inhibitor of RNA helicase A (RHA) (Tocris Bioactive Compound Library)
DESCRIPTION Docetaxel is a taxoid antineoplastic agent used in the treatment of various cancers, such as locally advanced or metastatic breast cancer, metastatic prostate cancer, gastric adenocarcinoma, and head and neck cancer. (Enamine Bioactive Compounds)
DESCRIPTION Docetaxel (RP-56976), a semi-synthetic analog of paclitaxel, is a microtubule depolymerization inhibitor (IC50=0.2 μM) that attenuates the effects of bcl-2 and bcl-xL gene expression and exhibits apoptosis-inducing, anti-tumor activity. (TargetMol Bioactive Compound Library)
Cell lines
611
Organisms
1
Compound Sets
35
AdooQ Bioactive Compound Library
A10326
Cayman Chemical Bioactives
11637
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL92
CHEMBL3545252
ChEMBL Drugs
CHEMBL92
CHEMBL3545252
Concise Guide to Pharmacology 2017/18
6809
Concise Guide to Pharmacology 2019/20
6809
Concise Guide to Pharmacology 2021/22
6809
Concise Guide to Pharmacology 2023/24
6809
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB01248
DrugBank Approved Drugs
DB01248
DrugCentral
939
DrugCentral Approved Drugs
939
DrugMAP
DMDI269
DrugMAP Approved Drugs
DMDI269
Enamine Bioactive Compounds
EBC-11238
Enamine BioReference Compounds
Guide to Pharmacology
6809
LINCS compound set
10247-101
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL3545252
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
CHEMBL3545252
Mcule NIBR MoA Box Subset
MCULE-3253978556
MedChem Express Bioactive Compound Library
HY-B0011
HY-B0011A
NCATS Inxight Approved Drugs
699121PHCA
NIH Approved Oncology Drugs
494081
Novartis Chemogenetic Library (NIBR MoA Box)
Nuisance compounds in cellular assays
Probe Miner (suitable probes)
P52732/981676
ReFrame library
TargetMol Bioactive Compound Library
T1034
Tocris Bioactive Compound Library
4056
Welcome Trust Cancer Drugs
1007
Withdrawn 2.0
EMA10
External IDs
71
Properties
(calculated by RDKit )
Molecular Weight
807.35
Hydrogen Bond Acceptors
14
Hydrogen Bond Donors
5
Rotatable Bonds
8
Ring Count
6
Aromatic Ring Count
2
cLogP
3.26
TPSA
224.45
Fraction CSP3
0.56
Chiral centers
11.0
Largest ring
8.0
QED
0.15
Structural alerts
1
Tubulin modulation
Nuisance compounds
Related compounds
Custom attributes
(extracted from source data)
Pathway
cytoskeleton
Cytoskeletal Signaling
Metabolism
Cell Cycle/DNA Damage
Metabolic Enzyme/Protease
Target
Microtubules
Tubulin
Apoptosis
Endogenous Metabolite
Microtubule
Microtubule/Tubulin
BCL2, MAP2, MAP4, MAPT, NR1I2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8
MOA
tubulin depolymerization inhibitor
Microtubule stabilizer
tubulin polymerization inhibitor
Member status
virtual
Indication
breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)
ATC
L01CD02
Therapeutic Class
Anticancer Agents
Source data